

International Journal of A J Institute of Medical Sciences 1 (2012) 93-97

Original Research Article

Lipid profile and Atherogenic index of plasma (AIP) in diabetic non smokers and smokers in coastal Karnataka

Sushith,¹ Jeevan Kumar Shetty,² Ashok Kumar Jeppu,¹ Prashantha Bhagavath,³ S.K. Shilpa,² M. Rashmi,² Vatsala Kamath,⁴ Sridhar Shetty⁵

¹Department of Biochemistry, A.J. Institute of Medical Sciences, Mangalore, India

²Department of Biochemistry, RAK College of Medical Sciences, RAKMHSU, Ras Al Khaimah, UAE

³Department of Forensic Medicine, Kasturba Medical College, Manipal University, Manipal, India

⁴Department of Obstetrics and Gynaecology, A.J. Institute of Medical Sciences, Mangalore, India

⁵Department of Orthopaedics, A.J. Institute of Medical Sciences, Mangalore, India

Abstract

Smoking is proven to be an independent risk factor for development of atherosclerosis and amongst diabetics it increases the risk of cardiovascular complications and stroke. Smoking is associated with increase in the serum concentrations of total cholesterol and very low-density lipoprotein cholesterol, and a decrease in serum high-density-lipoprotein cholesterol concentrations. Atherogenic index of plasma (AIP) is found to be useful marker in patients with diabetes as it increases the risk of cardiovascular disease. Present study was done to compare the lipid profile and AIP in diabetic non-smokers and diabetic smokers. There was significant increase in total cholesterol ($p<0.01$), triglycerides ($p<0.01$), TC/HC ratio ($p<0.001$) and AIP ($p<0.001$) and significant decrease in HDL ($p<0.05$) in diabetic patients who are smokers compared to diabetic patients who are non-smokers. According to the study, AIP could be used as a simple parameter to early assessment of risk for development of atherosclerosis in diabetic smokers.

© International Journal of A J Institute of Medical Sciences. All rights reserved.

Keywords: Atherosclerosis; Atherogenic index of plasma; Cardiovascular disease; Diabetes mellitus; Hyperlipidemia

Received 1st October, 2012; Accepted 28th October, 2012.

1. Introduction

Diabetes mellitus (DM) is a multi systemic metabolic disorder, showing common underlying features of hyperglycaemia, hyperlipidemia and vascular complications.^{1,2} Hyperlipidemia in diabetes mellitus is hallmarked by low plasma HDL-C and high LDL-C and triacylglycerol

levels, is common in patients with diabetes mellitus. These lipoprotein abnormalities are held to be responsible for considerable cardiovascular disease-related morbidity and mortality.³ High serum triglyceride levels are associated with the risk of developing cardiovascular disease independently of other major measured risk factors.⁴

Smoking is proven to be an independent risk factor for the development of atherosclerosis. Several studies have shown that nicotine in the smoke acts on the cholinergic receptors in the brain and autonomic ganglia. The binding of nicotine to these receptors, opens the ion channel, allowing the entry of sodium and calcium, which in turn, augment the release of neurotransmitters.⁵ The release of catecholamine and other neurotransmitters will increase the lipolysis and delivery of free fatty acids into the liver. In the liver free fatty acids undergo re esterification which in turn increases the concentration of VLDL. In diabetics, nicotine also produces insulin resistance which further enhances hyperglycaemia and its effects like atherosclerosis and coronary artery disease.⁶

Atherogenic index of plasma (AIP= log TG/HDL mmol/l) predicts the risk of development of atherosclerosis in diabetic patients as it considers the elevated levels of triglyceride as an important risk factor.⁷ Recent studies have shown that serum triglyceride level is an independent determinant of cardiovascular risk across a broad population group with abdominal obesity.⁸ The association of TGs and HDL-C in this simple ratio theoretically reflects the balance between risk and protective lipoprotein forces, and both TGs and HDL-C are widely measured and available.⁹

Present study was done to determine and compare the levels of fasting plasma glucose, fasting lipid profile, TC / HDL- C and AIP in diabetic non-smokers and diabetic smokers. To correlate the AIP with fasting plasma sugar (FPS) and lipid profile parameters.

2. Materials and methods

The study was carried out on total 72 patients and they were grouped into, group I consisting of 36 diabetic patients (mean age of 52 years) who are non smokers and group II consists of 36 diabetic patients (mean age of 53 years) who are smokers.

Patients involved in the study were recruited from Kasturba Medical College Hospital, Mangalore, India, with average history of diabetes mellitus from last 5-6 years. All of them are smokers with mean duration of smoking for about 16 years. Patients with history of alcoholism were excluded from the study. Subjects included in the study were having average 15 beedies/cigarettes per day. Informed consent was taken from all subjects involved in the study and was approved by the aforementioned institutional ethics committee. Fasting blood samples were also collected from group I and group II patients and serum was separated subsequently and processed for determination of fasting lipid profile and fasting plasma glucose.

Fasting lipid profile (TC, TG, HDLc) and Fasting plasma glucose was estimated by enzymatic method using automated analyzer Hitachi 917. FPG was determined by modified glucose oxidase/peroxidase method.¹⁰ Total cholesterol estimation was done by cholesterol oxidase method; high density lipoprotein was estimated by same method after precipitating the low density lipoproteins, very low density lipoprotein and chylomicrons.¹¹ Triglycerides were estimated by enzymatic mixture containing lipoprotein lipase, glycerol kinase and glycerol-3-phosphate oxidase and peroxidase.¹² LDL was calculated by Friedewald's formula ($LDL = TC - [HDL + TG/5]$), TC/HDLc was calculated by dividing total cholesterol by HDL cholesterol.¹³ AIP was calculated using formula, log TG /HDL, with TG and HDL expressed in molar concentrations. To convert mg/dl to mmol/L, divide the HDL cholesterol by 39 and triglyceride by 89.¹⁴

The results were expressed as mean \pm standard error of mean (SEM). A $p < 0.05$ was considered statistically significant. Statistical analysis was performed using the statistical package for social sciences (SPSS-16, Chicago, USA).

Independent sample t test was used to compare the mean values between cases and controls. Pearson correlation was applied to correlate between the parameters.

3. Results

As depicted in the table 1, there was significant

increase in total cholesterol ($p < 0.01$), triglycerides ($p < 0.01$), TC/HC ratio ($p < 0.001$) and AIP ($p < 0.001$) and significant decrease in HDL ($p < 0.05$) in group II patients compared to group I patients. As shown in figure 1, on applying Pearson's correlation there was significant positive correlation between FPG and AIP ($r = 0.433, p < 0.01$) in diabetic smokers.




Fig. 1: Correlation graph between fasting plasma glucose and AIP of plasma in diabetic smokers

Table 1: Comparison of lipid profile and AIP between diabetic smokers and non-smokers
(Values are expressed as mean \pm SD)

Parameters	Diabetic non smokers (n = 36)	Diabetic smokers (n = 36)
Age (years)	52 \pm 7	53 \pm 8
Weight (kilograms)	69 \pm 8.5	69 \pm 7.5
Duration of diabetes (years)	5 \pm 4	5.5 \pm 4.5
Type of diet (non veg /vegetarians)	25 + 11	26 + 10
Total cholesterol(mg/dl)	205 \pm 44	242 \pm 54**
Triglycerides(mg/dl)	177 \pm 57	265 \pm 127**
HDL (mg/dl)	37 \pm 8	33 \pm 8*
LDL (mg/dl)	132 \pm 40	146 \pm 57
TC/HC ratio	5.63 \pm 1.6	7.4 \pm 2.2***
AIP	0.241 \pm 0.306	0.490 \pm 0.196***
Fasting plasma glucose (mg/dl)	149 \pm 51	165 \pm 52

* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$

4. Discussion

In our study, we have found a significant increase in TC, TG, LDLc, TC/HDL ratio and FPG glucose and a significant decrease in HDLc in diabetic smokers compared to diabetic non smokers. Previous studies have shown dyslipidemia in diabetes mellitus is closely associated with insulin resistance and hyperglycaemia, which in turn increases the glycation of proteins and generation of reactive oxygen species together contributing for oxidation of LDL and atherosclerosis.¹⁵

According to our study lipid profile abnormalities were more severe in smokers compared to nonsmokers. The mechanisms responsible are not clearly elucidated; the triglyceride/ high-density lipoprotein abnormalities have recently been suggested to be related to insulin resistance.¹⁶ In fact, it has been proposed that insulin resistance is a potential key link between cigarette smoke and cardiovascular disease. In diabetic smokers, cigarette smoke contains many oxidizing substances which enhance the free radical levels and also free radical induced oxidation of LDL.^{17,18} Cigarette smoke extract exposure may also decrease the plasma activity of paraoxonase, an enzyme that protects against LDL oxidation.¹⁹ Thus smoking has added effect in the development of atherosclerosis in diabetic smokers, when compared to diabetic non smokers.

Although an independent, inverse relationship between HDL-C and cardiovascular risk has been demonstrated beyond any doubt, the contribution of TGs to cardiovascular risk has been underestimated. To overcome this, AIP was used, which takes both triglyceride and HDL levels in to consideration while calculating the atherogenicity and cardiovascular risk. Previous studies have indicated the role of AIP as early predictor of risk for development of atherosclerosis in diabetic patients. In line with previous studies, we also observed significant

increase in AIP in diabetic patients, which is further enhanced in smokers as compared to diabetic non smokers.⁷

Dobiasova and Frohlich proposed the term Atherogenic Index of Plasma (AIP), to consider the risk of triglyceride and defined as $\log(TG/HDL-C)$, on the basis that people with high AIP have a higher risk for coronary artery disease than those with low AIP, that AIP is positively correlated with the fractional esterification rate of HDL (FERHDL), and that AIP is inversely correlated with LDL particle size. Because FERHDL predicts particle size in HDL and LDL, which in turn predicts the risk of coronary heart disease, the simultaneous use of TGs and HDL-C (both readily available in a plasma lipoprotein profile) as AIP may be useful in predicting plasma atherogenicity. Furthermore, insulin resistance (decreased insulin sensitivity), which is often accompanied by increased coronary artery disease risk, is also often associated with increased TG and decreased HDL-C concentrations and a predominance of small, dense LDL particles. Thus by calculating AIP can give better idea in predicting the risk for development of atherosclerosis in diabetic patients.¹⁴

We have observed a significant positive correlation between FPG and AIP ($r= 0.434$, $p< 0.01$) in diabetic smokers. In diabetic smokers, prolonged hyperglycaemia and insulin resistance increases the lipogenesis and increases the triglyceride concentrations and decreases the HDLc and thus may contributing for elevation of AIP levels in diabetic smokers. Previous studies have indicated the role of cigarette smoke in attenuation of insulin resistance and exact mechanism is not clear.¹⁸ Thus in diabetic persons with poor glycaemic control and cigarette smoking has got elevated risk for development of atherosclerosis and coronary artery disease. In conclusion, AIP could be used as a simple parameter to early assessment of risk for

development of atherosclerosis in diabetic smokers.

References

1. Suvarna R, Rao SS, Joshi C, Kedage V, Muttagi MS, Shetty JK, Prakash M. Paraoxonase activity in type II patients with and without diabetes. *J Clin Dia Res* 2011;5:63-65.
2. Rother, KI. Diabetes Treatment - Bridging the Divide. *N Engl J Med* 2007;356: 1499-1501.
3. Pushpa K, Roopkala, Prasanna KM. Dyslipidemia in type I diabetes mellitus in the young. *Int J Diab Dev Countries* 2005; 25:110-112.
4. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Mänttari M, Heinonen OP, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki heart study. *Circulation* 1992;85:37-45.
5. Yeh HC, Duncan BB, Schmidt MI, Wang NY, Brancati FL. Smoking, smoking cessation and risk for type 2 diabetes mellitus: a cohort study. *Ann Intern Med* 2010; 152:10-17.
6. Audrain-McGovern J, Benowitz NL. Cigarette smoking, nicotine, and body weight. *Clin Pharmacol Ther* 2011;90:164-168.
7. Dobiasova M. Atherogenic index of plasma: Theoretical and practical implications. *Clin Chem* 2004;50:1113-1115.
8. Lamarche B, Després JP, Moorjani S, Cantin B, Dagenais GR, Lupien PJ. Prevalence of dyslipidemic phenotypes in ischemic heart disease. *Am J Cardiol* 1995;75:1189-1195.
9. Tan HM, Johns D, Bradly Glazer N. Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes mellitus. *Clin Chem* 2004;50:1184-1188.
10. Trinder P. Determination of blood glucose using an oxidaseperoxidase system with a non-carcinogenic chromogen. *J Clin Pathol* 1969;22:158-161.
11. Allain CC. Enzymatic determination of total cholesterol. *Clin Chem* 1974;20:470-477.
12. McGowan MW. An improved enzymatic method for determination of blood triglycerides by oxidase system. *Clin Chem* 1983;97:142-144.
13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 1972;18:499-502.
14. Dobiasova M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apo B-lipoprotein-depleted plasma. *Clin Biochem* 2001;34:583-588.
15. Suryawanshi NP, Bhutey AK, Nagdeote AN, Jadhav AA, Manorkar GS. Study of lipid peroxide and lipid profile in diabetes mellitus. *Indian J Clin Biochem* 2006;21:126-130.
16. Craig WY, Palomaki GE, Haddow JE. Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. *BMJ* 1989;298:784-788.
17. Ambrose AJ, Barua SR. The Pathophysiology of cigarette smoking and cardiovascular disease: An update. *J Am Coll Cardiol* 2004;43:1731-1737.
18. Reaven G, Tsao PS. Insulin resistance and compensatory hyperinsulinemia: the key player between cigarette smoking and cardio-vascular disease. *J Am Coll Cardiol* 2003;41:1044-1047.
19. Nishio E, Watanabe Y. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols. *Biochem Biophys Res Commun* 1997;236:289-293.

Corresponding author

Dr. Jeevan Kumar Shetty
Associate Professor
Department of Biochemistry,
RAK College of Medical Sciences
RAK, P.O. Box 11172, UAE
Mobile : +971 528113744
Email: drjkshetty1978@yahoo.com